DRIO Overview

DarioHealth Corp. is a global digital therapeutics (DTx) company delivering personalized evidence-based interventions that are driven by data analytics, software, and personalized coaching. The Company’s platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health. Its digital therapeutic platform has been designed with a user-first strategy, focusing on the user’s needs and user experience and satisfaction. Dario Blood Glucose Monitoring Starter Kit is a pocket-sized smartphone glucometer that manages diabetes in one ultra-compact device. Dario Blood Pressure Monitoring System is a blood pressure monitoring system used to measure blood pressure, which allows it to store all its user readings in the Dario App. The Dario mobile app is a complete, cloud-based solution for personal chronic condition management.

Wall Street analysts forecast DRIO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DRIO is13.50 USD with a low forecast of 11.00 USD and a high forecast of 16.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

DarioHealth Corp revenue for the last quarter amounts to 5.23M USD, decreased -31.21

DarioHealth Corp. EPS for the last quarter amounts to -1.14 USD, decreased -63.34

DarioHealth Corp (DRIO) has 196 emplpoyees as of March 25 2026.

Today DRIO has the market capitalization of 56.65M USD.